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Background:  Early  detection  of pulmonary  arterial  hypertension  (PAH)  is  indispensable,  although,  echo-
cardiography  at rest  alone  does  not  provide  sufﬁcient  evidence  for  it. Here,  this  study  aimed  to  investigate
the  usefulness  of  simple  exercise  echocardiography  using  a Master’s  two-step  test  for  detecting  early  PAH.
Methods: This  study  included  52 connective  tissue  disease  patients  who  had  mild  symptoms  in  World
Health  Organization  functional  classiﬁcation  2, suspected  as  having  early  PAH,  and  underwent  exer-
cise  echocardiography  and  right  heart  catheterization.  Echocardiography  was  performed  before  and
after the  Master’s  two-step  exercise  test; the  study  patients  were  classiﬁed  into  the  non-PAH  (mean
pulmonary  arterial  pressure  <  25 mmHg,  n  =  37)  or PAH  (mean  pulmonary  arterial  pressure  ≥ 25  mmHg,
n  =  15)  groups.
Results:  Rest  systolic  pulmonary  artery  pressure  estimated  using  echocardiography  did not  signiﬁcantly
differ  between  the  two  groups;  however,  a signiﬁcant  difference  in  post-exercise  systolic  pulmonary
artery  pressure  was  found  (non-PAH,  58.8 ± 10.8  mmHg;  PAH,  80.2  ± 14.3 mmHg,  p  < 0.0001).  The  mul-
tiple  logistic  regression  analysis  indicated  post-exercise  systolic  pulmonary  artery  pressure  as  an
independent  predictor  of PAH  (p  =  0.013).  The  area  under  the  curve  by  post-exercise  systolic  pulmonary
artery  pressure  was 0.91  for PAH.  Post-exercise  systolic  pulmonary  artery  pressure  ≥ 69.6  mmHg  pre-
dicted PAH  with  the  sensitivity  of 93%  and  the  speciﬁcity  of  90%.
Conclusions:  Simple  exercise  echocardiography  using  the  Master’s  two-step  test could  detect  PAH in
mildly  symptomatic  connective  tissue  disease  patients.  The  usefulness  of  this  method  should  be veriﬁed
 PAH.
3  Japfor  the  early  detection  of
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One of the speciﬁc natures of pulmonary arterial hypertension
PAH) is the remodeling of small pulmonary vessels which is
haracterized by increases in pulmonary arterial pressure (PAP)
nd pulmonary vascular resistance [1]. PAH is a pathophysiological
tate deﬁned by an increase in mean PAP (mPAP) ≥ 25 mmHg
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awasaki, Kanagawa 216-8511, Japan. Tel.: +81 44 977 8111x3313;
ax: +81 44 976 7093.
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during rest conﬁrmed by right heart catheterization (RHC) [1,2].
PAH is often diagnosed in its advanced stage because no speciﬁc
symptoms, signs, or abnormal echocardiographic indices were
found in early-stage PAH [3,4]. RHC is considered the gold standard
for PAP measurement, although, it is not applicable to a broader
population because of its invasive nature and costs. Nowadays,
clinical outcomes are dramatically improved in early PAH patients
determined by World Health Organization functional classiﬁcation
2 and mPAP ≥ 25 mmHg  [5,6]. However, the clinical method for
early detection of PAH has not been fully established.Generally, patients with connective tissue disease (CTD) are at
a high risk of developing PAH [7]. Current guidelines recommend
annual echocardiographic screening for the detection of PAH in
patients with systemic sclerosis [8]. The early detection of PAH is
vier Ltd. All rights reserved.
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hus vitally important, although, echocardiography at rest alone is
imited by its low sensitivity [9,10]. Exercise echocardiography is
 reliable means of differentiating physiologic and pathologic pul-
onary PAP responses, however, it is only provided in facilities
quipped with a half-sitting ergometer [11]. Therefore, simple, safe,
nd reliable exercise echocardiography should be established [12].
ere, we employed a Master’s two-step test for exercise echocardi-
graphy and evaluated its usefulness for the early detection of PAH
n patients with CTD.
aterials and methods
tudy patients
A total of 300 consecutive patients with CTD in World Health
rganization functional classiﬁcation 2 who had clinically unex-
lained mild shortness of breath and subsequently underwent
xercise echocardiography between August 2010 and August 2012
ere prospectively identiﬁed. Of these, the following patients
ere excluded from this study: patients with previous history of
AH or systolic PAP (sPAP) ≥ 50 mmHg  at rest [1], severe restric-
ive lung disease (forced vital capacity < 80% of the predicted
alue), left ventricular (LV) systolic dysfunction (LV ejection frac-
ion < 60%), LV diastolic dysfunction [the ratio of peak early diastolic
itral inﬂow velocity (E) and peak early diastolic mitral annular
elocity (e′); E/e′ ≥ 15], signiﬁcant valvular disease, systemic hyper-
ension (resting systolic values > 150 mmHg  or resting diastolic
alues > 90 mmHg  on medication), those who could not perform
he exercise stress test, and those with poor quality of echocardi-
graphic imaging. Age- and gender-matched controls (n = 37) were
lso enrolled in this study.
chocardiography at rest and post exercise
Echocardiography was performed using a commercially avail-
ble ultrasound machine (Artida, Toshiba Medical Systems, Tokyo,
apan) equipped with a 2.5-MHz transducer. Two-dimensional
chocardiography measured each chamber dimension, volume,
nd wall thickness according to the recommendation described
y the American Society of Echocardiography [13]. Mitral inﬂow
as analyzed for E, peak late diastolic velocity (A) and E/A ratio
nd deceleration time of E. e′ was derived from the mean values
btained at both the septal and lateral mitral annulus in the apical
ig. 1. Tricuspid regurgitation (TR) at rest and post exercise. At rest, TR velocity was 2.7 m
xercise, TR velocity was 4.2 m/s  and estimated sPAP was  71 mmHg. In this case, mean pul
6  mmHg.ology 62 (2013) 176–182 177
4-chamber view using tissue Doppler imaging. The E/e′ ratio was
measured to estimate LV ﬁlling pressure [14]. sPAP was  estimated
from the peak tricuspid regurgitation (TR) jet according to the
simpliﬁed Bernoulli equation (sPAP = 4 × v2 + right atrial pressure),
where “v” was  the peak velocity of TR jet (m/s); right atrial pressure
was estimated from the diameter and breath-induced variability
of the inferior vena cava [15]. All patients underwent the Master’s
double two-step exercise test. The number of steps was determined
by age, gender, and weight of the patients [16]. Immediately after
exercise, the patients laid down on a bed and underwent another
echocardiography for the measurements of post-exercise, post 3-
min, and post 5-min sPAP (Fig. 1). At the same time, blood pressure
and heart rate were also measured.
RHC
The patients received RHC according to the transjugular
approach using a 7Fr quadruple-lumen balloon-tipped ﬂow-
directed Swan-Ganz catheter (Edwards Lifesciences; Irvine, CA,
USA). PAP was monitored and averaged over several respiratory
cycles during spontaneous breathing. sPAP, mPAP, pulmonary arte-
rial wedge pressure, and right atrial pressure were measured.
Cardiac output was  measured according to the thermodilution
technique using an analog computer system (Nihon Koden, Tokyo,
Japan). Pulmonary vascular resistance was  derived from the dif-
ference between mPAP and pulmonary arterial wedge pressure
divided by cardiac output [17].
Statistical analysis
Statistical analysis was performed using commercially avail-
able software (SPSS 18.0 software, SPSS Inc., Chicago, IL, USA).
All continuous data were reported as mean ± SD and categorical
data as percentage. The level of p < 0.05 was  considered statis-
tically signiﬁcant. Obtained variables between the groups were
compared using the one-way analysis of variance, Tukey’s test,
and chi-square test. The correlation between sPAP estimated using
echocardiography and mPAP measured by RHC was  analyzed
according to the Pearson correlation coefﬁcient. The multivari-
able logistic regression analysis was performed to evaluate the
association of PAH with echocardiographic parameters obtained
at rest and post exercise. The analysis included age, gender, body
mass index, post-exercise systolic blood pressure, and rest and
/s  and estimated systolic pulmonary artery pressure (sPAP) was  29 mmHg. At post
monary arterial pressure (mPAP) measured by right-side heart catheterization was
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ost-exercise sPAP because these variables were closely associated
ith PAP [18].
thics
The present study was performed in accordance with the eth-
cal principles set forth in the Declaration of Helsinki. The study
rotocol was approved by the St. Marianna University School of
edicine Institutional Committee on Human Resource, Kawasaki,
apan (No. 1798). The participants were well informed prior to the
est; written informed consent was obtained before enrollment.
esults
Of the 300 patients with CTD screened for inclusion criteria,
0 patients were excluded because of severe restrictive lung dis-
ase (n = 10), systolic (n = 2) and diastolic (n = 12) LV dysfunction,
igniﬁcant valvular disease (n = 8), and uncontrolled systemic
ypertension (n = 12), and poor quality of TR jet (n = 16). Of the
emaining 240 patients, 220 (92%) completely underwent exercise
chocardiography within 20 s (mean 17.2 ± 1.8 s) and 20 patients
8%) were excluded because of exceeded exercise time and poor
chocardiographic imaging qualities. No patients complained of
hest symptoms throughout the examination. Of the 220 patients,
08 (49%) revealed exercise-induced pulmonary hypertension
rest sPAP < 50 mmHg  and post-exercise sPAP ≥ 50 mmHg). Of
hese, 68 patients with poor exercise capacity determined by
-min walking distance less than 400 m were suggested to receive
HC; ﬁnally, 52 patients underwent RHC (Fig. 2). Of these, 36
atients (69%) had systemic sclerosis, 8 patients (15%) had mixed
TD, 5 patients (10%) had systemic lupus erythematodes, and 3
atients (6%) had Sjögren syndrome.
ig. 2. Flowchart representing the algorithm and the assessments of the study. WHO  
ressure; 6MW,  6-min walking; RHC, right-side heart catheterization; PAH, pulmonary aology 62 (2013) 176–182
Patients’ characteristics and echocardiographic parameters
The patients were classiﬁed into the non-PAH
(mPAP < 25 mmHg, n = 37) or PAH (mPAP ≥ 25 mmHg, n = 15)
group based on mPAP measured by RHC. No signiﬁcant differences
in age, gender, body mass index, log brain natriuretic peptide,
or carbon monoxide diffusion capacity by body surface were
found between the non-PAH and PAH groups, although, signiﬁcant
differences in pulmonary arterial wedge pressure (p < 0.0001) and
pulmonary vascular resistance were found (p = 0.003) (Table 1).
Meanwhile, no signiﬁcant differences in conventional echocar-
diographic parameters were found between the non-PAH group,
PAH group and controls, but post-exercise blood pressure and
heart rate were higher in the non-PAH and PAH groups than the
controls (Table 2).
Rest and post-exercise sPAP
There was  a trend toward higher rest sPAP in the PAH and non-
PAH groups than the controls. Rest sPAP did not signiﬁcantly differ
between the non-PAH and PAH groups; however, signiﬁcant dif-
ferences in post-exercise, post 3-min and post 5-min sPAP were
found between the non-PAH and PAH groups (p < 0.0001) (Table 2
and Fig. 3). The recovery of sPAP was slower in the PAH group than
the other groups.
Association between mPAP and sPAP
A moderate correlation was found between rest sPAP estimated
using echocardiography and mPAP measured by RHC (r = 0.529,
p < 0.0001). In the PAH group, compared to mPAP, rest sPAP under-
estimated the severity of pulmonary hypertension. Meanwhile,
a strong correlation was  found between post-exercise sPAP and
FC, World Health Organization Functional Class; sPAP, systolic pulmonary artery
rterial hypertension; mPAP, mean pulmonary artery pressure.
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Table  1
Patients’ characteristics.
Controls Non-PAH
mPAP < 25 mmHg
PAH
mPAP ≥ 25 mmHg
(n  = 37) (n = 37) (n = 15)
Age 59.0 ± 5.8 56.0 ± 12.6 58 ± 14.8
Female 32 (86%) 31 (84%) 12 (80%)
Height (cm) 158.3 ± 7.0 154.9 ± 6.9 158.1 ± 9.5
Body  weight (kg) 49.0 ± 8.4 48.6 ± 8.2 52.3 ± 9.3
Body  mass index 21.0 ± 1.4 20.2 ± 2.8 20.8 ± 2.8
6MWD  (m) –  411.4 ± 93.8 374.2 ± 58.9†
SSc – 26 (70%) 10 (67%)
CTD  except SSc – 11 (30%) 5 (33%)
Log  BNP – 2.03 ± 0.24 2.10 ± 0.26
%DLco (%) – 53.5 ± 16.1 39.6 ± 13.6
mPAP  (mmHg) – 17.0 ± 4.1 32.1 ± 7.4†
PAWP (mmHg) – 8.2 ± 4.1 10.5 ± 2.3†
PVR (dynes s m2 cm5) – 112.2 ± 52.9 286.9 ± 101.6†
CO (L/min) – 6.0 ± 1.3 6.7 ± 2.2
Rest  SBP/DBP (mmHg) 120.3 ± 25.5/69.0 ± 11.7 113.7 ± 24.2/64. 1 ± 9.8 118.6 ± 14.2/66.6 ± 11.1
Rest  heart rate (bpm) 72.2 ± 13.1 74.6 ± 11.6 79.7 ± 16.4
Post  SBP/DBP (mmHg) 137.3 ± 25.0/81.6 ± 21.3 145.2 ± 24.8*/75.9 ± 13.2 148. 7 ± 24.6**/82.0 ± 13.4
Post  heart rate (bpm) 86.1 ± 14.8 104.1 ± 22.2* 118. 7 ± 10.2**
PAH, pulmonary arterial hypertension; 6MWD,  6-min-walk distance; SSc, systemic sclerosis; CTD, connective tissue disease; BNP, brain natriuretic peptide; %DLco, carbon
monoxide diffusion capacity by body surface; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance; CO,
cardiac  output; SBP, systolic blood pressure; DBP, diastolic blood pressure.
* p < 0.05, controls vs. non-PAH.
** p < 0.05, controls vs. PAH.
† p < 0.05, non-PAH vs. PAH.
Table 2
Echocardiographic parameters.
Controls Non-PAH
mPAP < 25 mmHg
PAH
mPAP ≥ 25 mmHg
(n  = 37) (n = 37) (n = 15)
LAD (mm)  32.7 ± 4.5 33.7 ± 5.3 37.1 ± 7.2**
LAVI (mL/m2) 23.3 ± 5.8 30.7 ± 12.7* 31.6 ± 10.8**
Septal thickness (mm)  8.3 ± 1.3 8.2 ± 1.4 8.5 ± 0.9
PW  thickness (mm)  8.3 ± 1.2 8.7 ± 1.4 9.0 ± 1.5
LVDd  (mm)  44.6 ± 4.5 44.4 ± 5.4 44.7 ± 4.7
LVDs  (mm)  27.8 ± 2.9 26.4 ± 4.2 28.3 ± 4.7
LVEF  (%) 67.5 ± 4.6 69.5 ± 7.2 69.5 ± 6.7
E/A  0.88 ± 0.23 1.11 ± 0.23 1.02 ± 0.82
Dct  (ms) 199.0 ± 35.8 208.9 ± 64.7 215.3 ± 73.0
e′ (cm/s) 8.7 ± 1.7 8.8 ± 2.8* 8.0 ± 1.9**
E/e′ 7.1 ± 1.6 9.3 ± 3.6* 9.5 ± 4.2**
Rest sPAP (mmHg) 22.2 ± 4.7 36.4 ± 6.6* 41.6 ± 7.4**
Post-exercise sPAP (mmHg) 31.0 ± 8.4 58.8 ± 10.8* 80.2 ± 14.3**,†
Post 3-min sPAP (mmHg) 27.5 ± 5.3 49.7 ± 8.7* 75.1 ± 17.4**,†
Post 5-min sPAP (mmHg) 24.5 ± 4.3 43.8 ± 8.0* 63.9 ± 14.4**,†
PAH, pulmonary arterial hypertension; LAD, left atrial diameter; LAVI, left atrial volume index; PW,  posterior wall; LVDd, left ventricular end-diastolic diameter; LVDs, left
ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; E/A, the ratio of early diastolic (E) and late diastolic (A) transmitral inﬂow velocities; Dct, deceleration
time  of E wave velocity; E/e′ , the ratio of early diastolic transmitral ﬂow velocity to early diastolic mitral annular velocity; sPAP, systolic pulmonary artery pressure.
m
e
M
a
d
R
p
f* p < 0.05, controls vs. non-PAH.
** p < 0.05, controls vs. PAH.
† p < 0.05, non-PAH vs. PAH.
PAP (r = 0.711, p < 0.0001); post-exercise sPAP could accurately
stimate mPAP in the PAH group (Fig. 4).
ultivariable logistic regression analysis for predicting PAH
The data obtained from the multivariable logistic regression
nalysis suggested that post-exercise sPAP should be an indepen-
ent predictor of PAH (p = 0.013) (Table 3).
eceiver operating characteristic curve based on rest and
ost-exercise sPAP for predicting PAH
The receiver operating characteristic analysis was performed
or predicting PAH (mPAP ≥ 25 mmHg) on a basis of rest andpost-exercise sPAP. The area under curve by rest sPAP was  0.79 (95%
conﬁdence interval: 0.65–0.93) for PAH; the area under curve by
post-exercise sPAP was  0.91 (95% conﬁdence interval: 0.82–0.99)
for PAH. Post-exercise sPAP ≥ 69.6 mmHg  predicted PAH with the
sensitivity of 93% and the speciﬁcity of 90% (Fig. 5).
Discussion
The results of this study demonstrated that sPAP estimated
using echocardiography after the Master’s two-step exercise could
detect PAH in CTD patients in World Health Organization functional
classiﬁcation 2. This exercise echocardiography using a Master’s
two-step test was simple, safe, and reliable for the early detection
of PAH.
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Fig. 3. Changes in systolic pulmonary artery pressure (sPAP) at rest and post exercise. No signiﬁcant difference in rest sPAP estimated using echocardiography was found
between the pulmonary arterial hypertension (PAH) and non-PAH groups. However, signiﬁcant differences in post-exercise, post 3-min, and post 5-min sPAP were found
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cetween the two groups (non-PAH: 58.8 ± 10.8 mmHg, 49.7 ± 8.7 mmHg, and 43.8
AH,  pulmonary arterial hypertension; sPAP, systolic artery pressure; post, post-ex
imitations of echocardiography at rest
Echocardiography at rest is the most widely used screening
ethod for detecting PAH because it not only provides a reason-
bly reliable and comprehensive assessment of the right heart and
ulmonary circulation but also helps to exclude any secondary
auses of pulmonary hypertension [11]. The main target in the
ig. 4. Association between mPAP and sPAP. The moderate correlation was  found betwe
ound  between post-exercise sPAP and mPAP (r = 0.711, p < 0.0001). mPAP, mean pulmona
atheterization; PAH, pulmonary arterial hypertension.mHg; PAH: 80.2 ± 14.3 mmHg, 75.1 ± 17.4 mmHg, 63.9 ± 14.4 mmHg, p < 0.0001).
; 3-min, post 3-minute; 5-min, post 5-minute.
detection of pulmonary hypertension is sPAP estimated from TR
jet; however, interpretable TR jet at rest cannot be obtained in
approximately 10–20% of patients in the assessment of pulmonary
hypertension [19]. Particularly, the assessment of TR jet remains
difﬁcult in patients with early PAH. When the quality of TR jet
is poor, sPAP is possibly underestimated, potentially leading to
delayed or inaccurate diagnosis. In the present study, compared
en rest sPAP and mPAP (r = 0.52, p < 0.0001). Meanwhile, a strong correlation was
ry artery pressure; sPAP, systolic pulmonary artery pressure; RHC, right-side heart
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Table  3
Multivariable logistic regression analysis for predicting pulmonary arterial hypertension.
Independent variable Univariate analysis Multivariate analysis
Odds ratio 95% CI p Value Odds ratio 95% CI p Value
Age 1.025 0.983–1.069 0.250 1.009 0.878–1.160 0.898
Gender 0.236 0.046–1.219 0.085 1.005 0.824–1.120 0.997
BMI  1.081 0.877–1.333 0.466 1.872 0.987–3.552 0.055
Post-exercise SBP 1.001 0.979–1.024 0.912 0.975 0.930–1.023 0.308
Rest  sPAP 1.167 1.057–1.290 0.002 1.226 0.921–1.632 0.164
Post-exercise sPAP 1.192 1.073–1.323 0.001 1.459 1.081–1.968 0.013
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sI, conﬁdence interval; BMI, body mass index; SBP, systolic blood pressure; sPAP, s
o mPAP measured by RHC, rest sPAP estimated using echocardi-
graphy underestimated the severity of pulmonary hypertension
n the PAH group.
orrelation between mPAP and sPAP
Our study results demonstrated the strong correlation between
PAP measured by RHC and post-exercise sPAP estimated using
chocardiography (r = 0.711, p < 0.0001). The European guidelines
or the diagnosis and treatment of pulmonary hypertension [1]
ave described the echocardiographic diagnosis of pulmonary
ypertension “likely” when sPAP is >50 mmHg  and pulmonary
ypertension “possible” when sPAP is between 37 and 50 mmHg.
hen we adopted the above-mentioned classiﬁcation in our PAH
roup, only 2 patients were classiﬁed to pulmonary hyperten-
ion “likely” and most of the patients to pulmonary hypertension
possible”, suggesting that echocardiography at rest should under-
stimate the PAH group. Meanwhile, echocardiography at post
xercise is probably useful for accurate diagnosis in the PAH group
hen the cut-off value is set at approximately 70 mmHg. Data
btained from post-exercise echocardiography images provide
dditional ﬁndings for conﬁrming pulmonary hypertension “pos-
ible”. Argiento et al. [20] have demonstrated that a high level of
ig. 5. Receiver operating characteristic curve based on rest and post-exercise sPAP for 
nder  the curve by post-exercise sPAP was 0.91 for PAH. Post-exercise sPAP ≥ 69.6 mmHg
PAP,  systolic pulmonary artery pressure; PAH, pulmonary arterial hypertension; mPAP, m pulmonary artery pressure.
training and dedication allows for 88% of good-quality TR signals
for the study of pulmonary hemodynamics during exercise.
Mechanism of exercise-induced increases in PAP
Exercise echocardiography may  uncover a familial predisposi-
tion to PAH that is not detectable during rest [21,22]. An abnormal
exercise-induced increase in PAP can be ascribed to a rise in
pulmonary vascular resistance due to limited capability of the
pulmonary vascular bed. Furthermore, alveolar hypoxia, which is
increased levels of catecholamine, vasopressin, and endothelin 1
and a potent pulmonary vasoconstrictor [23–25], is believed to
play a crucial role in an increase in PAP during exercise [23]. An
elevated PAP on exercise may  be caused by not only pulmonary
vasculopathy but also a signiﬁcant increase in left ventricular
ﬁlling pressure. Kovacs et al. [26] demonstrated that, even when
echocardiography showed no signs of LV systolic or diastolic dys-
function, RHC revealed an elevation of pulmonary arterial wedge
pressure > 20 mmHg  in 33% of patients with exercise-induced PAP
increases, which might suggest a latent LV ﬁlling dysfunction.
The present study excluded patients with LV systolic and diastolic
dysfunction, although, latent LV ﬁlling dysfunction might inﬂuence
the increases in exercise-induced PAP. D’Alto et al. [27] reported
predicting PAH. The area under the curve by rest sPAP was  0.79 for PAH; the area
 predicted mPAP ≥ 25 mmHg with the sensitivity of 93% and the speciﬁcity of 90%.
ean pulmonary artery pressure; AUC, area under the curve; CI, conﬁdence interval.
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hat high PAP response to exercise was related to subclinical echo-
ardiographic evidence of LV diastolic dysfunction. The inﬂuence
f LV ﬁlling pressure on exercise-induced increases in PAP should
e evaluated in our further studies.
aster’s two-step exercise echocardiography
The uniqueness of the present study is the use of a Master’s two-
tep test which is widely employed for the detection of ischemic
eart disease since Master [16] standardized electrocardiographic
ndings. The main drawback using this equipment is that patients
erform this exercise test in the standing position without warm-
ng up and lie down on bed right after exercise, which may  cause
n increase in venous return and abrupt overload of the heart.
atients with moderate to severe PAH must not undergo this exer-
ise test because vital signs are not monitored during the test which
ay  trigger unexpected circulatory collapse. Occasionally, some
atients with moderate and severe PAH had no obvious symptoms.
hese patients must be observed very carefully by experts while
ndergoing this exercise echocardiography.
imitations
The present study is the ﬁrst attempt to employ a Master’s two-
tep test for the detection of PAH. It remains unclear whether this
ethod is useful in a multi-center trial because this approach has
ot been validated by clinical investigation yet. Further studies with
 larger population are thus required. Exercise echocardiography is
sually performed using an ergometer, and sPAP is estimated dur-
ng exercise. In this study, post-exercise sPAP was measured right
fter patients lying down on bed; therefore, time lag in each patient
ay  inﬂuence sPAP. More data accumulation is indispensable for
he establishment of this simple exercise echocardiography.
onclusions
The results of this study demonstrated that simple exercise
chocardiography using the Master’s two-step test could detect
AH in mildly symptomatic CTD patients. The usefulness of this
ethod should be veriﬁed for the early detection of PAH.
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